RxDoctor Payments Data

Peter Pasley, MD

Internal Medicine · New York, NYNPI 1104840503

Payments from drug & device makers

$549in general payments, 2019–2025

Across 29 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$113
  • Gilead$71
  • Amarin Pharma, Inc.$69
  • Novo Nordisk$60
  • Boehringer Ingelheim$44
  • Neurocrine Biosciences, Inc.$39
  • plus $153 from 9 others

What the payments were for

  • Food & beverage$549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$549 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$182,796
Medicare patients
303
Services billed
2,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$130,677
JanuviaSitagliptin Phosphate48$62,924
OzempicSemaglutide35$39,850
MounjaroTirzepatide22$26,840
XareltoRivaroxaban41$20,239
EntrestoSacubitril/Valsartan33$19,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,155
FarxigaDapagliflozin Propanediol26$14,742
Enoxaparin Sodium94$11,605
SantylCollagenase Clostridium Hist.22$10,912
Atorvastatin Calcium557$7,249
BriviactBrivaracetam15$7,237
Breo ElliptaFluticasone/Vilanterol19$7,154
Sevelamer Hcl13$6,097
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$130,677318 claims
MerckJanuvia$113$62,92448 claims
Novo NordiskOzempic$60$39,85035 claims
Lilly USA, LLCMounjaro$15$26,84022 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$17$26,54950 claims
Johnson & JohnsonXarelto$14$20,23941 claims
NovartisEntresto$12$19,87633 claims
Boehringer IngelheimStiolto Respimat$44$5,63711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →